 | Up a level |
Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19. LONDON: BMC. ISSN 1471-2407
Wuchter, Patrick, Bertsch, Uta, Salwender, Hans-Juergen, Munder, Markus, Haenel, Mathias, Benner, Axel, Becker, Natalia, Fenk, Roland, Duerig, Jan, Blau, Igor Wolfgang, Lisenko, Katharina, Hillengass, Jens, Raab, Marc S., Baertsch, Marc Andrea, Seidel-Glaetzer, Andrea, Ho, Anthony D., Graeven, Ullrich, Scheid, Christof, Weisel, Katja and Goldschmidt, Hartmut (2016). Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020